文献速递消化道肿瘤与早癌消化内镜

seAFOod息肉预防试验参与后的结直肠息肉结局:短期阿司匹林使用后结直肠息肉风险反弹升高的证据

Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use.
PubMed 文献 · Aliment Pharmacol Ther · 2023-07-30

seAFOod试验是阿司匹林300 mg与二十碳五烯酸(EPA)2000 mg每日的2×2析因随机安慰剂对照试验。507例参与者在试验后接受监测结肠镜检查,安慰剂阿司匹林组息肉检出率为71.1%,阿司匹林组为80.1%(OR 1.13,95%CI 1.02–1.24,p=0.02);EPA与安慰剂无差异(OR 1.00,95%CI 0.91–1.10,p=0.92)。

要点

  • 试验后监测中,曾用阿司匹林者息肉检出率80.1%,高于安慰剂阿司匹林组的71.1%(OR 1.13)。
  • EPA与安慰剂组结直肠息肉结局无差异(息肉检出率OR 1.00,95%CI 0.91–1.10,p=0.92)。
  • 作者认为短期阿司匹林使用后肿瘤风险反弹升高,对因年龄相关出血风险而停用阿司匹林有重要含义。

核心结论

  • 在seAFOod试验中接受阿司匹林的个体在试验后监测期间结直肠息肉风险增加。
  • 短期阿司匹林使用后肿瘤风险反弹升高,对因年龄相关出血风险而停用阿司匹林有重要含义。

研究设计与样本

  • seAFOod息肉预防试验为随机、安慰剂对照的2×2析因试验,比较阿司匹林300 mg与EPA 2000 mg每日。
  • 受试者为在英国肠道癌症筛查计划(BCSP)中接受筛查结肠镜检查的个体。
  • 共507例个体在试验参与后接受一次或多次结肠镜检查,按原试验治疗分配分组,随访至试验参与后6年。

主要发现

  • 随机分配至安慰剂阿司匹林的个体息肉检出率(PDR)为71.1%。
  • 接受阿司匹林的个体PDR为80.1%(OR 1.13,95%CI 1.02–1.24,p=0.02)。
  • 分配至EPA与安慰剂的个体结直肠息肉结局无差异(PDR的OR 1.00,95%CI 0.91–1.10,p=0.92)。
  • 按治疗分配分组的人群在临床特征、随访时长和监测结肠镜检查次数方面匹配良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The seAFOod polyp prevention trial was a randomised, placebo-controlled, 2 × 2 factorial trial of aspirin 300 mg and eicosapentaenoic acid (EPA) 2000 mg daily in individuals who had a screening colonoscopy in the English Bowel Cancer Screening Programme (BCSP). Aspirin treatment was associated with a 20% reduction in colorectal polyp number at BCSP surveillance colonoscopy 12 months later. It is unclear what happens to colorectal polyp risk after short-term aspirin use. AIM: To investigate colorectal polyp risk according to the original trial treatment allocation, up to 6 years after trial participation. METHODS: All seAFOod trial participants were scheduled for further BCSP surveillance and provided informed consent for the collection of colonoscopy outcomes. We linked BCSP colonoscopy data to trial outcomes data. RESULTS: In total, 507 individuals underwent one or more colonoscopies after trial participation. Individuals grouped by treatment allocation were well matched for clinical characteristics, follow-up duration and number of surveillance colonoscopies. The polyp detection rate (PDR; the number of individuals who had ≥1 colorectal polyp detected) after randomization to placebo aspirin was 71.1%. The PDR was 80.1% for individuals who had received aspirin (odds ratio [OR] 1.13 [95% confidence interval 1.02, 1.24]; p = 0.02). There was no difference in colorectal polyp outcomes between individuals who had been allocated to EPA compared with its placebo (OR for PDR 1.00 [0.91, 1.10]; p = 0.92). CONCLUSION: Individuals who received aspirin in the seAFOod trial demonstrated increased colorectal polyp risk during post-trial surveillance. Rebound elevated neoplastic risk after short-term aspirin use has important implications for aspirin cessation driven by age-related bleeding risk. ISRCTN05926847.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Downing A, Fenton H, Nickerson C, et al. Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use. Aliment Pharmacol Ther. 2023. PMID: 37518954. doi:10.1111/apt.17646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。